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The application of radiofrequency ablation for the treatment of lung cancer by our group at 
Okayama University Graduate School of Medicine,  Dentistry and Pharmaceutical Sciences began in 
June 2001,  and in the present report,  we review our 10-year experience with this treatment modality 
at Okayama University Hospital.  The local eﬃcacy of radiofrequency ablation for the treatment of 
lung cancer depends on tumor size and the type of electrode used,  but not on tumor type.  An impor-
tant factor for the prevention of local failure may be the acquisition of an adequate ablative margin.  
The combination of embolization and radiation therapy enhances the local eﬃcacy.  Local failure may 
be salvaged by repeating the radiofrequency ablation,  particularly in small tumors.  Survival rates 
after radiofrequency ablation are quite promising for patients with clinical stage I non-small cell lung 
cancer and pulmonary metastasis from colorectal cancer,  hepatocellular carcinoma,  and renal cell 
carcinoma.  The complications caused by radiofrequency ablation can be treated conservatively in the 
majority of cases.  However,  attention should be paid to rare but serious complications.  This review 
shows that radiofrequency ablation is a promising treatment for patients with lung cancer.
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rimary lung cancer is currently the most com-
mon cause of cancer-related death in the world.  
Furthermore,  the lung is one of the most common 
sites of metastases from various primary sites.  
Surgical resection is currently the most curative 
therapy for lung cancer,  whether primary or meta-
static.  However,  surgery is not a feasible option for 
many patients with lung cancer.  Research aimed at 
ﬁnding an alternative therapy for lung cancer has 
therefore been extensive in the past decades.
　 Radiofrequency ablation (RFA) has received con-
siderable attention as a local therapy for hepatocellu-
lar carcinoma.  The favorable outcomes of RFA for 
hepatocellular carcinoma have encouraged the applica-
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tion of this technique to neoplasms in other organs,  
including the lungs.  The application of RFA for the 
treatment of lung cancer by our group at Okayama 
University Graduate School of Medicine,  Dentistry 
and Pharmaceutical Sciences began in June 2001,  and 
during these past 10 years,  several ablation sessions 
for lung neoplasms have been carried out.  In the pres-
ent report,  we review our 10-year experience with 
RFA of lung cancer at Okayama University Hospital.
Our Standard Protocol
　 Approval from the institutional review board and 
informed consent from the patients were obtained to 
perform RFA of lung cancer.  Our institutional review 
board also provided approval to report retrospective 
studies using the outcomes of RFA.
　 Preprocedural examination. A complete 
blood count,  blood biochemistry values,  and blood 
coagulation proﬁle are obtained before each RFA 
treatment session.  Chest computed tomography (CT) 
scanning is performed to assess the tumors and to 
guide the procedure.  The scan includes the abdomen 
to evaluate extrapulmonary metastasis.  Positron 
emission tomography is also performed whenever pos-
sible.  Pulmonary function tests are carried out in 
most cases,  in particular for patients at risk for 
developing pulmonary dysfunction,  including patients 
with a history of pulmonary surgery and radiation and 
those with underlying lung disease such as chronic 
obstructive lung disease.
　 RFA is indicated in those patients for whom the 
treatment of lung cancer is expected to contribute to 
prolonged survival and/or improved quality of life.  
The procedure is not indicated in patients with leuko-
penia,  thrombopenia,  coagulation disturbances,  or 
substantial organ dysfunction.  For example,  patients 
with a leucocyte count of＜3,000cells/µl,  a platelet 
count of＜50,000/ul,  a prothrombin time-international 
ratio of＞1.5,  poor pulmonary function (predicted 
forced respiratory volume in 1 secｦ1,000ml),  and/or 
poor cardiac function (New York Heart Association 
ClassｧⅢ) are not candidates for RFA.
　 Procedure techniques. The RFA procedure is 
performed as in-patient treatment.  All procedures are 
performed percutaneously using CT-ﬂuoroscopic guid-
ance by an experienced interventional radiologist or a 
radiology trainee (resident or fellow) under the super-
vision of an experienced interventional radiologist 
(Fig.  1).  The patients are usually placed in a supine 
or prone position,  depending on the tumor location.  
Standard steel mesh grounding pads are placed on the 
patientʼs thighs.  Blood pressure,  pulse,  blood satura-
tion,  and electrocardiogram are monitored throughout 
the procedure.
　 The electrode used for the procedure is a single 
internally cooled electrode with a 1-,  2-,  or 3-cm 
noninsulated tip (Cool-tip; Covidien,  Mansﬁeld,  MA,  
USA) or a multitined expandable electrode with a 2-,  
3-,  3.5-,  or 4-cm array diameter (LeVeen; Boston 
Scientiﬁc,  Natick,  MA,  USA).  A cluster internally 
cooled electrode (Covidien) was used for the treatment 
of large tumors during our early experience.  However,  
the use of the cluster electrode was currently sus-
pended because of the high likelihood of complications 
(see the “Complications” section).  Until October 2003,  
an internally cooled electrode was the only type of 
electrode available at our institution,  and thus it was 
used for all procedures.  After that,  multitined 
expandable electrodes became available,  and they are 
currently the preferred electrode for the RFA proce-
dure based on data showing a signiﬁcant improvement 
in the local eﬃcacy compared to the internally cooled 
electrode (see the “Local tumor control” section).  A 
single internally cooled electrode is alternatively used 
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Fig. 1　 A picture during radiofrequency ablation under CT ﬂuoro-
scopic guidance.  CT ﬂuoroscopic images are displayed on the 
screen (arrow) immediately after a physician steps on a foot switch.  
The CT gantry is moved in the cephalocaudal direction for a patient 
by handling the controller (arrowhead).  Thereby,  a physician is able 
to adjust the scanning level of the image.
when the use of the multitined expandable electrode is 
deemed unsuitable.
　 Intraprocedural pain is treated by using local 
anesthesia or local plus epidural anesthesia,  along 
with conscious sedation with an intravenous drip infu-
sion of fentanyl and an intramuscular injection of 
hydroxyzine.  In the case of expected severe proce-
dural pain,  e.g.,  when the tumor is close to the pleura,  
or if the patient asks for it,  epidural anesthesia is 
administered.  After the administration of anesthesia,  
the electrode is introduced into the tumor and con-
nected to the generator (CC-1,  Covidien,  for inter-
nally cooled electrodes or RF3000,  Boston Scientiﬁc,  
for multitined expandable electrodes).  The ablation 
algorithm according to electrode type is shown in 
Table 1.  For the Covidien devices,  an impedance-
control algorithm is selected,  and the initial radiofre-
quency power is set at 20W or 30W according to the 
electrodes with noninsulated tip lengths (Table 1).  
The power is increased by 10W/min (Table 1).  
Radiofrequency energy is applied for 12min during 
infusion of ice saline into the cooling lumen of the 
electrode.  Immediately after radiofrequency applica-
tion,  the temperature of the tumor at the electrode tip 
is measured.  Whenever the temperature fails to reach 
60℃,  additional radiofrequency applications are 
attempted at the same site.
　 For the Boston Scientiﬁc device,  the radiofre-
quency power is set at 10-40W according to the array 
diameter; the power is then increased at the rate of 
5W/min or 10W/min (Table 1).  Radiofrequency 
energy is applied until a dramatic increase in imped-
ance occurs or automatic shut-oﬀ occurs at 15min.  
After a 30-sec interval,  the second radiofrequency 
energy application is performed at the same site,  with 
the initial power set at half of the maximum power 
used in the ﬁrst application.  The second radiofre-
quency energy application is also ended when there is 
a dramatic increase in impedance or automatic shut-oﬀ 
at 15min.  The procedure is aimed at achieving abla-
tion of the entire tumor,  including a parenchymal 
margin of at least 5mm,  and multiple overlapping 
ablations are performed whenever deemed necessary 
to cover the entire area.
　 Immediately after completion of the procedure,  CT 
images of the lung are obtained to assess the ablation 
zone and procedural complications.  An upright chest 
posteroanterior radiograph is obtained 3h later and 
again the following morning,  mainly to evaluate the 
occurrence and the severity of pneumothorax.  A 
symptomatic pneumothorax or a pneumothorax that 
exceeds 30-40ｵ of the hemothorax is usually treated 
with chest tube placement.
　 Follow-up. CT images in cases of complete 
ablation and local progression are shown in Fig.  2 and 
3,  respectively.  Patients are followed up at 1,  3,  6,  
9,  and 12 months and thereafter at 6-month intervals 
with chest and abdominal CT images with a contrast 
medium,  whenever possible.  The local eﬃcacy is 
evaluated mainly based on sequential follow-up CT 
images.  During the ﬁrst 3 months of follow-up,  the 
size of the ablated lesion may exceed the tumor size 
before ablation,  due to the detection of the entire 
ablated lesion including the marginal parenchyma 
(Fig.  2,  3).  Thus,  CT images obtained 1 month after 
RFA are taken as a term of reference.  Thereafter,  
the local eﬃcacy may be evaluated by comparing the 
size and geometry of the ablation zone with the obser-
vations of the previous CT images.  Local tumor pro-
gression is considered to have occurred when the 
ablation zone is circumferentially enlarged or when an 
irregular,  scattered,  nodular,  or eccentric focus 
appears in the ablation zone (Fig.  3).  This focus 
generally exhibits some degree of contrast enhance-
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Table 1　 Ablation algorithm according to electrode type
Noninsulated tip length 
or arrays diameter (cm) Initial power (W) Increased rate of power (W/min)
Internally cooled electrode 2 20 10
3 30 10
Multitined expandable electrode 2 10 5
3 20 5
3.5 30 10
4 40 10
ment and is thus distinguished from the unenhanced 
necrotic tumor tissue.
　 Although positron emission tomography is not 
included in our routine follow-up imaging protocol,  it 
is performed,  when deemed necessary,  to evaluate 
local progression and regional and distant metastases.
Ten-year Outcomes
　 Feasibility. We ﬁrst described the preliminary 
results of RFA for the treatment of lung cancer in 
2004 [1].  At the time of that report,  we had per-
formed RFA in 99 primary or metastatic lung cancers.  
The reported technical success rate was 100ｵ.  
Complications were reported after 76ｵ of the ses-
sions.  The local control rate was 91ｵ during the 
mean follow-up period of 7 months.  Thereafter,  we 
reported the feasibility of RFA based on our ﬁrst 
3.5-year experience [2].  This study reported the 
results of 211 RFA sessions for the treatment of 366 
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Fig. 2　 CT images in a case of complete ablation.  A,  CT ﬂuoroscopic image during RFA shows that a multitined expandable electrode 
is introduced into pulmonary metastasis from colon cancer measuring 1.5cm in diameter in the right upper lobe.  The arrow indicates the 
electrode shaft,  and the arrowheads indicate the expanded tines; B,  CT image 1 month after RFA shows that the size of the ablated 
lesion exceeds the tumor size before RFA due to the detection of the entire ablated lesion including the marginal parenchyma.  The arrow 
indicates an electrode tract; C,  CT image 4 month after RFA shows shrinkage of the ablated lesion; D,  CT image 16 months after RFA 
shows the ablated lesion as scar-like tissue,  suggesting complete ablation.
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Fig. 3　 CT images in a case of local progression.  A,  CT image before RFA shows pulmonary metastasis from colon cancer measuring 
1.8cm in diameter in the right lower lobe; B,  CT ﬂuoroscopic image during RFA shows that a multitined expandable electrode is intro-
duced into the tumor.  The black arrow indicates the electrode shaft,  and the arrowheads indicate the expanded tines.  The white arrows 
indicate pneumothorax; C,  CT image 1 month after RFA shows that the size of the ablated lesion exceeds the tumor size before RFA,  due 
to the detection of the entire ablated lesion,  including the marginal parenchyma; D,  CT image 7 month after RFA shows shrinkage of the 
ablated lesion; E,  CT image 7 month after RFA at the upper level of image D shows nodular focus (arrow) at the upper margin of the 
ablated lesion,  suggesting local progression.
tumors in 137 patients.  After 211 ablation sessions,  
there was no procedural mortality,  but there were 2 
procedure-related deaths (0.9ｵ) that were attributed 
to intractable pneumothorax and massive hemorrhage.
　 Local tumor control.
　 1. Risk factors for local progression. A study 
by us analyzed preliminary local control outcomes and 
the factors aﬀecting local control [3].  The local 
control rates of 342 tumors were 72ｵ at 1 year,  
60ｵ at 2 years,  and 58ｵ at 3 years.  The local pro-
gression rate after RFA of lung cancer appeared 
higher than that observed after RFA of hepatocellular 
carcinoma and renal cell carcinoma.  Unlike solid 
organs,  the lungs possess intrinsically unique tissue 
characteristics that aﬀect the outcome of RFA.  The 
limited electrical and thermal conductivity of the air-
containing lung tissues can interfere with the achieve-
ment of an adequate ablative margin.  Furthermore,  
ventilation promotes a heat sink eﬀect and thus may 
inhibit the increase in tissue temperature.  These fac-
tors may contribute to inferior local control outcomes 
in the lung.  The signiﬁcant risk factors for local 
progression determined by univariate analysis were 
male gender,  tumor diameter ofｧ2cm,  central loca-
tion,  contact with a blood vessel,  contact with a 
bronchus,  use of an internally cooled electrode,  and 
an estimated ratio of the ablation volume to the tumor 
volume of＜3.0.  The independent risk factors for 
local progression determined by multivariate analysis 
were larger tumor size and the use of an internally 
cooled electrode.  When considering tumors without 
the independent risk factors (i.e.,  tumors＜2cm in size 
that were treated with a multitined expandable elec-
trode),  the technique eﬀectiveness rates were 89ｵ at 
1 year and 66ｵ at 2 years.
　 2. Tumor type. In addition to tumor size and 
electrode type,  the local control outcomes can also be 
determined by tumor type due to a variety of factors 
related to the cytology,  pathophysiology,  and biology 
of the tumor.  The sensitivity of cells to heat may vary 
with cell type.  The presence of intratumoral septa and 
tumor capsules can aﬀect thermal distribution during 
RFA.  A more inﬁltrating tumor theoretically has a 
higher risk of local progression.  Considering the 
perfusion-mediated heat sink eﬀect,  RFA treatment of 
hypervascular tumors can be associated with decreased 
thermal eﬀects.  We examined the eﬀect of tumor type 
on local control outcomes [4].  First,  we evaluated 
the local control outcomes of a total of 5 types of 
cancer: primary lung cancer and pulmonary metasta-
ses from colorectal cancer,  lung cancer,  renal cell 
carcinoma,  and hepatocellular carcinoma.  The overall 
local control rates were 86ｵ and 76ｵ at 1 and 2 
years,  respectively.  Metastatic colorectal cancer 
showed signiﬁcantly higher local control rates than 
those of the other 4 types.  However,  these results 
alone were insuﬃcient to prove that tumor type aﬀects 
local control,  because the distribution of other factors 
aﬀecting local control was heterogeneous among the 
groups.  Univariate analysis showed that tumor size,  
tumor contact with a vessel or bronchus,  and tumor 
treatment during the ﬁrst 2 years were signiﬁcantly 
associated with inferior local tumor control.  
Therefore,  to evaluate the eﬀect of tumor type on 
local control,  we carried out a multivariate analysis to 
adjust for the diﬀerences in these factors and found 
that the relative risk of local progression was similar 
among the 5 tumor types.  In other words,  this study 
proved that RFA may provide similar local eﬃcacy,  
independent of tumor type.
　 3. Tumor location. One area of concern with 
regard to RFA for the treatment of lung cancer is the 
safety and eﬀectiveness of the procedure in the case 
of tumors that are in the proximity of the heart or the 
aorta.  In these cases,  possible complications include 
the accidental insertion of an electrode into the heart 
or the aorta and thermal injury to cardiac components 
such as the pericardium,  myocardium,  and coronary 
artery,  resulting in pericardial eﬀusion,  arrhythmia,  
and cardiac infarction,  respectively.  In addition,  the 
eﬀectiveness might be reduced by the pulsation of 
these structures and a considerable heat sink eﬀect 
caused by high blood ﬂow.  In a study designed to 
evaluate the safety and eﬀectiveness of RFA applied 
to tumors in the proximity of the heart or the aorta 
[5],  we analyzed the eﬀects of RFA of 42 tumors 
that were less than 10mm from the heart or the aorta.  
These tumors were classiﬁed into 2 groups: group A 
was composed of 27 tumors that were close to but 
separate from the heart or the aorta; group B 
included 15 tumors that were contiguous to the heart 
or the aorta.  RFA treatment was feasible for all 42 
tumors.  There were no complications associated with 
the speciﬁc tumor location,  such as the accidental 
insertion of the electrode into the heart or aorta,  
pericardial eﬀusion,  arrhythmia,  or cardiac infarc-
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tion.  The local control rate in group A was 69ｵ at 2 
years,  compared to only 9ｵ at 1 year in group B.  
The results of this study indicated that although RFA 
could be safely performed in tumors near the heart or 
aorta,  the local control of tumors contiguous to the 
heart or the aorta was quite limited.
　 4. Repeat RFA for local progression. One 
notable advantage of RFA may be the ability to repeat 
the procedure in cases of local failure.  We analyzed 
the signiﬁcance of repetition of the procedure for local 
tumor control [6].  Out of 797 tumors treated from 
June 2001 to February 2007,  117 tumors were diag-
nosed as showing local progression.  The primary local 
control rate was 74ｵ at 1 year,  64ｵ at 2 years,  
63ｵ at 3 years,  and 63ｵ at 4 years.  Among the 117 
locally progressing tumors,  56 tumors were treated by 
repeat RFA.  Of these 56 tumors,  17 tumors showed 
local progression for the second time.  The secondary 
local control rate,  namely,  the local control rate of 
both the ﬁrst and the second RFA,  was 88ｵ at 1 
year,  79ｵ at 2 years,  74ｵ at 3 years,  and 74ｵ at 
4 years.  The secondary local control rates were sig-
niﬁcantly higher than the primary rates,  which sug-
gested that repetition of the procedure contributed to 
better local tumor control.  However,  the results also 
revealed the limitations of the repeat RFA treatment.  
Tumor sizeｧ2cm at the ﬁrst RFA and contact with 
bronchi or vessels were signiﬁcant risk factors for 
local control by the repeat RFA.  The local control 
rate was limited to 40ｵ at 2 years for tumors with 
one or more risk factors,  even if the procedure was 
repeated in cases of local failure.
　 5. Single RF application with multitined 
expandable electrodes. The area of radiofre-
quency-induced coagulation is largely dependent on the 
noninsulated tip length of internally cooled electrodes 
or the diameter of the arrays of multitined expandable 
electrodes.  In addition,  as described above,  the 
electrode type (internally cooled electrode vs.  multi-
tined expandable electrode) may aﬀect the local con-
trol outcomes.  The ideal tumor candidates for RFA 
should therefore be determined based on the charac-
teristics of the speciﬁc electrode,  including its type 
and noninsulated tip length or the diameter of the 
arrays.  However,  the determination of ideal tumor 
candidates for RFA based on electrode type is not well 
understood.  We aimed at determining which tumors 
are most likely to respond favorably to RFA involving 
a single RF application with a single type of electrode 
(multitined expandable electrode with arrays measur-
ing 2cm in diameter) [7].  A retrospective evaluation 
of 88 lung metastases (mean long-axis diameter,  
0.9cm) treated with a single RF application with such 
an electrode showed overall local control rates of 92ｵ 
at 1 year and 90ｵ at 2 years.  Tumor size＞1.0cm 
and contact with the bronchus were the signiﬁcant risk 
factors for local progression.  The local control rates 
for the 59 tumorsｦ1.0cm that were not in contact 
with the bronchus were 96ｵ each at 1 year and at 2 
years.  These results suggested that lung metastases
ｦ1.0cm that were not in contact with the bronchus 
were favorable responders for a single RF application 
with a multitined expandable electrode with arrays 
2cm in diameter.
　 Patient survival. Survival outcomes of 
patients with various lung cancers treated with RFA 
are summarized in Table 2.
　 1. Clinical stage I non-small cell lung cancer.
In 2007,  we analyzed patient survival after RFA in 
20 nonsurgical candidates with clinical stage I non-
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Table 2　 Summary of survival outcomes of patients with various lung cancers treated by radiofrequency ablation
Reference 
number
Cancer type
No. of
patients
Follow-up
period (months)
Survival rate (%) Survival time (months)
1 year 2 years 3 years 4 years 5 years Median Mean
8 Stage I NSCLC 20 22 (median) 90 84 74 42
9 Stage I NSCLC 50 37 (median) 94 86 74 67 61 67 59
10 Metastases from CRC 27 20 (median) 96 54 48 33
11 Metastases from CRC 71 19 (mean) 84 62 46 31
13 Metastases from HCC 32 21 (median) 87 57 57 38 43
14 Metastases from RCC 15＊ 25＊ (mean) 100＊ 100＊ 100＊ 100＊ 100＊
NSCLC,  non-small cell lung cancer; CRC,  colorecal cancer; HCC,  hepatocellular carcinoma; RCC,  renal cell carcinoma.
＊Data are derived from curative group.
small cell lung cancer [8].  During the median follow-
up period of 21.8 months,  the overall survival rates 
were 90ｵ at 1 year,  84ｵ at 2 years,  and 74ｵ at 3 
years; the cancer-speciﬁc survival rates were 100ｵ 
at 1 year,  93ｵ at 2 years,  and 83ｵ at 3 years.  The 
mean survival time was 42 months.  In an additional 
study in 2011,  we analyzed survival outcomes after 
RFA in patients with clinical stage I non-small cell 
lung cancer,  using a larger population and longer fol-
low-up periods [9].  The study included 50 patients 
with a median follow-up period of 37 months.  The 
overall survival rates were 94ｵ at 1 year,  86ｵ at 2 
years,  74ｵ at 3 years,  67ｵ at 4 years,  and 61ｵ at 
5 years.  The median and mean survival times were 67 
months and 59 months,  respectively.  The cancer-
speciﬁc survival rates were 100ｵ at 1 year,  93ｵ at 
2 years,  80ｵ at 3 years,  80ｵ at 4 years,  and 74ｵ 
at 5 years; the disease-free survival rates were 82ｵ 
at 1 year,  64ｵ at 2 years,  53ｵ at 3 years,  46ｵ at 
4 years,  and 46ｵ at 5 years.  Considering that the 
population included nonsurgical candidates,  the 
reported midterm survival data seem quite promising.  
At the same time,  however,  it should be noted that 
such promising survival data depends,  in part,  on 
selection bias; the population had relatively small 
cancers (mean tumor size,  2.1cm) and included a high 
proportion (20ｵ,  10/50) of patients with cancer 
showing pure ground-glass opacity.
　 Considering unsatisfactory survival of the patients 
with stage IB or II disease by standard surgery alone,  
we feel that RFA combined with concurrent chemo-
therapy and RFA supported by adjuvant chemotherapy 
for stage IB or II disease would be interesting and 
should be considered in a future trial.
　 2. Pulmonary metastasis from colorectal can-
cer. We also assessed survival rates in patients 
with pulmonary metastases from colorectal cancer 
[10].  This study included 27 patients having a total 
of 49 pulmonary metastases (mean long-axis diameter,  
1.5cm) from colorectal cancer.  During the median 
follow-up period of 20.1 months after RFA,  the over-
all survival rates were 96ｵ at 1 year,  54ｵ at 2 
years,  and 48ｵ at 3 years.  The most signiﬁcant 
prognostic factor was the presence of extrapulmonary 
metastasis at the time of RFA.  Similar favorable 
survival (46ｵ at 3 years) was reported by a multi-
center study in Japan involving Okayama University 
Hospital [11].
　 3. Pulmonary metastases from hepatocellular 
carcinoma. With regard to pulmonary metastases 
from hepatocellular carcinoma,  we reported on 2 
promising cases of patients who survived for 86 
months and 75 months,  respectively,  after RFA of 
pulmonary metastases with no evidence of cancer 
recurrence [12].  We conducted a multicenter study 
involving 6 institutions in Japan to investigate survival 
after pulmonary metastases from hepatocellular carci-
noma [13].  This study included 32 patients who had 
no intrahepatic recurrence or had treatable intrahe-
patic recurrence,  who had no other metastases,  and 
for whom RFA was performed with curative intent 
(i.e.,  not palliatively).  The overall survival rates were 
87ｵ at 1 year and 57ｵ at 2 and 3 years during a 
median follow-up period of 20.5 months.  Signiﬁcantly 
better survival rates were obtained for patients with 
an absence of viable intrahepatic recurrence,  Child-
Pugh grade A,  absence of liver cirrhosis,  absence of 
hepatic C virus infection,  and α-fetoprotein levelsｦ
10ng/ml at the time of RFA.
　 4. Pulmonary metastases from renal cell carci-
noma. In cases of pulmonary metastases from renal 
cell carcinoma,  patient survival was evaluated using 
data from 2 institutions,  including Okayama University 
Hospital [14].  This study included 39 nonsurgical 
candidates who were divided into 2 groups: a curative 
ablation group,  which was formed by 15 patients with 
6 or fewer lung metastases measuringｦ6cm that were 
conﬁned to the lung and who had all lung tumors 
ablated,  and the palliative ablation group,  which 
included 24 patients with extrapulmonary lesions,  7 
or more lung tumors,  or large tumors of＞6cm,  and 
who had mass reduction.  The overall survival rates in 
the curative and palliative ablation groups were 100ｵ 
and 90ｵ at 1 year,  100ｵ and 52ｵ at 3 years,  and 
100ｵ and 52ｵ at 5 years,  respectively.  The maximum 
lung tumor diameter was a signiﬁcant prognostic factor.
　 Complications. The incidence of various com-
plications by RFA is summarized in Table 3.
　 1. Pneumothorax. Pneumothorax is the most 
common complication following RFA.  We evaluated 
the incidence of pneumothorax after RFA of lung 
cancer [15] and found an incidence rate of 52ｵ.  
Risk factors for pneumothorax included male gender,  
no history of pulmonary surgery,  a greater number of 
tumors ablated,  involvement of the middle or lower 
lobes,  and increased length of the aerated lung tra-
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versed by the electrode.  Among those aﬀected,  21ｵ 
of the pneumothoraces required chest tube treatment.  
The risk factors for chest tube placement for pneu-
mothorax included no history of pulmonary surgery,  
the use of a cluster electrode,  and involvement of the 
upper lobe.
　 2. Pleural eﬀusion. In the same study [15],  we 
also evaluated the incidence and risk factors associ-
ated with the development of pleural eﬀusion.  The 
incidence of pleural eﬀusion reported in this study was 
19ｵ,  and the majority of these cases were treated 
conservatively.  The signiﬁcant risk factors associated 
with the development of pleural eﬀusion were the use 
of a cluster electrode,  decreased distance to the near-
est pleura,  and a decrease in the length of the aerated 
lung that was traversed by the electrode.  We investi-
gated the relationship between pleural temperature 
and pleural events (e.g.,  pneumothorax and pleural 
eﬀusion) after the RFA of lung tumors [16].  The 
occurrence of pleural eﬀusion was shown to be associ-
ated with higher pleural temperatures during the 
procedure,  whereas pneumothorax was not related to 
pleural temperature.
　 3. Bronchopleural ﬁstula. Although pneu-
mothorax can usually be treated conservatively or via 
the placement of a chest tube without the persistence 
of air leakage,  we reported on 2 cases of intractable 
pneumothorax resulting from the development of a 
bronchopleural ﬁstula [17].  The incidence of intrac-
table pneumothorax due to bronchopleural ﬁstula in 
our series was 0.6ｵ (2/334).  In both cases,  RFA 
induced necrosis of the lung tissue between the pleural 
space and the bronchus.  The bronchopleural ﬁstula 
formed after sloughing of the necrotic tissue.  
Management of the bronchopleural ﬁstula was quite 
challenging,  requiring various treatment modalities 
that included pleurodesis,  endobronchial management,  
and/or surgical repair.  In one case,  air leakage per-
sisted despite these eﬀorts,  and the patient died of 
acute pneumonia 52 days after the procedure.
　 4. Needle-tract seeding. Rare but important 
complications of RFA treatment for lung cancer were 
reported by us,  including 2 cases of needle-tract seed-
ing [18],  4 cases of brachial nerve injury [19],  and 
1 case of Aspergillus infection [20].  The frequency of 
needle-tract seeding after RFA of lung tumors was 
0.5ｵ (2/374) for patients,  0.3ｵ (2/661) for proce-
dures,  and 0.2ｵ (2/1,024) for tumors.  In both of the 
needle tract seeding cases,  RFA was performed with 
a single internally cooled electrode; the electrode tip 
temperature immediately after radiofrequency applica-
tion was＜60℃; the electrode was then removed 
without cauterizing the electrode tract.  The conclu-
sions of the study were that cancer cells attached to 
the electrode tip may remain viable even after radiof-
requency application and become detached along the 
tract during removal of the electrode.
　 5. Brachial nerve injury. The rate of incidence 
of brachial nerve injury was 0.5ｵ (4 of 733 proce-
dures),  and in all 4 cases,  the treated tumor was in 
the lung apex.  When the analysis was conﬁned to the 
procedures for apical lung cancer,  the incidence of 
brachial nerve injury was 15ｵ (4 of 26).  The patients 
developed symptoms of a low brachial plexus injury,  
which,  despite partially receding over time,  remained 
a grade 2 injury in 3 patients and a grade 3 injury in 
1 patient (according to the National Cancer Institute 
Common Terminology Criteria for Adverse Events,  
version 4.0).
　 6. Aspergillus infection. With regard to the 
single reported case of aspergilloma,  a large cavity 
was formed after the RFA for lung cancer,  which 
resulted in a scaﬀold for Aspergillus infection.  We 
suggested that the possibility of aspergilloma should 
be considered in the case of consolidation formed in a 
cavity after RFA,  and it should be diﬀerentiated from 
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Table 3　 Summary of incidence of various complications of radiofrequency ablation
Reference number Complication Incidence for procedures (%)
15 Pneumothorax 52
15 Pleural eﬀusion 19
17 Bronchopleural ﬁstula 0.6
18 Needle-tract seeding 0.3
19 Brachial nerve injury 0.5
21 Pulmonary artery pseudoaneurysm 0.2
local tumor progression.
　 7. Pulmonary artery pseudoaneurysm. We 
reported another rare (0.2ｵ,  1 of 538 procedures) 
but serious complication after lung RFA: pulmonary 
pseudoaneurysm that caused massive hemoptysis and 
was successfully treated with transcatheter coil embo-
lization [21].
　 Attempts to enhance the eﬃcacy of RFA.
　 1. Pulmonary artery embolization. In an 
attempt to enhance the local eﬃcacy of RFA in the 
lungs,  studies were conducted on animal models [22,  
23].  We noted a heat sink eﬀect in the pulmonary 
artery that may decrease the thermal eﬀect during RFA.  
We therefore performed RFA after pulmonary artery 
embolization using degradable starch microspheres in a 
porcine lung model [22].  As expected,  RFA after pul-
monary artery embolization resulted in signiﬁcantly 
enlarged coagulation compared with RFA alone.
　 2. Infusion of saline into the lung. We also 
noted that alveolar air was an obstacle to ablation,  
because air has limited electrical and thermal conduc-
tivity.  Therefore,  we infused hypertonic saline into 
the lung parenchyma immediately before and during 
RFA [23].  RFA with infusion of saline into the lung 
successfully enlarged coagulation compared with RFA 
without it.
　 3. Combination therapy. In the clinical setting,  
we described 2 cases of large (6cm and 5.5cm in size) 
primary lung cancer treated with RFA followed by 
conventional radiation therapy [24].  Radiation ther-
apy was initiated 2 months or 10 days after RFA.  The 
radiation dose administered was 50Gy per 25 frac-
tions or 60Gy per 30 fractions.  The tumors were well 
controlled until patient death 17 months or 6 months 
after the therapy.  We also reported a case of com-
plete treatment of a 4.7-cm hypervascular pulmonary 
metastasis from a hepatocellular carcinoma close to the 
pulmonary hilum [25].  Transcatheter embolization,  
then RFA,  and lastly external beam radiation were 
applied to eradicate the tumor.  Transcatheter embo-
lization may enhance the eﬀect of the subsequent RFA 
by decreasing blood ﬂow.  RFA treatment might 
improve the eﬃcacy of subsequent radiation treat-
ment,  because the eﬀect of radiation therapy depends 
on tumor volume,  and RFA can considerably reduce 
viable tumor volume.  The combination of RFA with 
diﬀerent therapeutic modalities can therefore be of 
great beneﬁt not only through an additive eﬀect but 
also due to synergistic eﬀects.
　 4. Pain control during procedures. Pain 
control during RFA for lung cancer is an important 
concern.  Intraprocedural pain is more prominent when 
treating tumors close to the pleura.  The parietal 
pleura and chest wall are sensitive to pain because 
abundant sensory nerve branches originate at the 
intercostal nerve,  contrary to the visceral pleura and 
lung parenchyma.  We induced artiﬁcial pneumothorax 
during RFA in 7 cases to reduce procedural pain 
[26].  Artiﬁcial pneumothorax was induced as follows:  
the multitined expandable electrode was placed in the 
tumor,  and the tines were fully expanded.  The elec-
trode was then pushed forward by applying pressure,  
thereby creating a space in the pleural cavity.  If pain 
relief was not satisfactory,  an 18-gauge intravenous 
catheter was introduced into the pleural cavity,  and 
CO2 was administered through the catheter to enlarge 
the pleural cavity.  All 7 cases experienced consider-
able pain relief after the induction of artiﬁcial pneu-
mothorax.
Conclusions
　 The local eﬃcacy of RFA for the treatment of lung 
cancer depends on tumor size and the type of electrode 
used,  but not on tumor type.  An important factor for 
the prevention of local failure may be the acquisition 
of an adequate ablative margin.  The combination of 
embolization and radiation therapy enhances the local 
eﬃcacy.  Local failure may be salvaged by repeating 
the RFA,  particularly in small tumors.  Survival rates 
after RFA are quite promising for patients with clini-
cal stage I non-small cell lung cancer and pulmonary 
metastasis from colorectal cancer,  hepatocellular 
carcinoma,  and renal cell carcinoma.  The complica-
tions caused by RFA can be treated conservatively in 
the majority of cases.  However,  attention should be 
paid to rare but serious complications.
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